Mesenchymal stem cells: A good candidate for restenosis therapy?

Current Vascular Pharmacology

Volumn 7, Issue 3, 2009, Pages 381-393

  Forte, Amalia ^a   Galderisi, Umberto ^a   Cipollaro, Marilena ^a   Cascino, Antonino ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Angioplasty; Homing; Immunosuppression; Mesenchymal stem stromal cells; Negative remodeling; Restenosis

Indexed keywords

ADENOVIRUS VECTOR; NITROPRUSSIDE SODIUM; TELOMERASE;

ANGIOPLASTY; BLOOD VESSEL INJURY; BONE MARROW BIOPSY; BYPASS SURGERY; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; CELL ISOLATION; CELL TYPE; CLINICAL TRIAL; ENDARTERECTOMY; ENZYME ACTIVITY; HUMAN; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; KARYOTYPE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYME CELL; MULTIPOTENT STEM CELL; NONHUMAN; PATHOPHYSIOLOGY; RESTENOSIS; REVASCULARIZATION; REVIEW; STEM CELL; STROMA CELL; TISSUE INJURY; TISSUE REGENERATION; ANIMAL; CELL MOTION; INCIDENCE; MESENCHYMAL STEM CELL; METHODOLOGY; PHYSIOLOGY; SEXUAL DEVELOPMENT;

ANIMALS; CELL MOVEMENT; CORONARY RESTENOSIS; HUMANS; INCIDENCE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; SEX CHARACTERISTICS;

EID: 69149104287     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016109788340776     Document Type: Review

References (136)

1. Pasterkamp G, de Kleijn DP, Borst C. Arterial remodeling in atherosclerosis, restenosis and after alteration of blood flow: potential mechanisms and clinical implications. Cardiovasc Res 2000; 45: 843-52.
2. Schmidt MR, Maeng M, Kristiansen SB, Andersen HR, Falk E. The natural history of collagen and alpha-actin expression after coronary angioplasty. Cardiovasc Pathol 2004; 13: 260-7.
3. Lafont A, Durand E, Samuel JL, Besse B, Addad F, Levy BI, et al. Endothelial dysfunction and collagen accumulation: two independent factors for restenosis and constrictive remodeling after experimental angioplasty. Circulation 1999; 100: 1109-15.
4. Forte A, Finicelli M, De Luca P, Quarto C, Onorati F, Sante P, et al. Expression profiles in surgically-induced carotid stenosis: A combined transcriptomic and proteomic investigation. J Cell Mol Med 2007.
5. Shirayoshi Y, Yuasa Y, Suzuki T, Sugaya K, Kawase E, Ikemura T, et al. Proto-oncogene of int-3, a mouse Notch homologue, is expressed in endothelial cells during early embryogenesis. Genes Cells 1997; 2: 213-24.
6. Lawson ND, Scheer N, Pham VN, Kim CH, Chitnis AB, Campos-Ortega JA, et al. Notch signaling is required for arterial-venous differentiation during embryonic vascular development. Development 2001; 128: 3675-83.
7. Lugus JJ, Park C, Choi K. Developmental relationship between hematopoietic and endothelial cells. Immunol Res 2005; 32: 57-74.
8. Aoki J, Serruys PW, van Beusekom H, Ong AT, McFadden EP, Sianos G, et al. Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) Registry. J Am Coll Cardiol 2005; 45: 1574-9.
9. Bertolino P, Deckers M, Lebrin F, Ten Dijke P. Transforming growth factor-beta signal transduction in angiogenesis and vascular disorders. Chest 2005; 128(6 Suppl): 585S-90S.
10. Khurana R, Zhuang Z, Bhardwaj S, Murakami M, De Muinck E, Yla-Herttuala S, et al. Angiogenesis-dependent and independent phases of intimal hyperplasia. Circulation 2004; 110: 2436-43.
11. Heikki P, Timo W, Nureddin A, Sampsa V. Degeneration and regeneration of perivascular innervation in arterial grafts. J Craniofac Surg 2004; 15: 570-81; discussion 82-4.
12. Candipan RC, Hsiun PT, Pratt R, Cooke JP. Vascular injury augments adrenergic neurotransmission. Circulation 1994; 89: 777-84.
13. Rey FE, Pagano PJ. The reactive adventitia: fibroblast oxidase in vascular function. Arterioscler Thromb Vasc Biol 2002; 22: 1962-71.
14. Noishiki Y, Tomizawa Y, Yamane Y, Matsumoto A. Autocrine angiogenic vascular prosthesis with bone marrow transplantation. Nat Med 1996; 2: 90-3.
15. Hinz B. Formation and function of the myofibroblast during tissue repair. J Invest Dermatol 2007; 127: 526-37.
16. Gabbiani G, Ryan GB, Majne G. Presence of modified fibroblasts in granulation tissue and their possible role in wound contraction. Experientia 1971; 27: 549-50.
17. Bellini A, Mattoli S. The role of the fibrocyte, a bone marrow-derived mesenchymal progenitor, in reactive and reparative fibroses. Lab Invest 2007; 87: 858-70.
18. Wilcox JN, Cipolla GD, Martin FH, Simonet L, Dunn B, Ross CE, et al. Contribution of adventitial myofibroblasts to vascular remodeling and lesion formation after experimental angioplasty in pig coronary arteries. Ann N Y Acad Sci 1997; 811: 437-47.
19. Yoshida T, Sinha S, Dandre F, Wamhoff BR, Hoofnagle MH, Kremer BE, et al. Myocardin is a key regulator of CArG-dependent transcription of multiple smooth muscle marker genes. Circ Res 2003; 92: 856-64.
20. Gan Q, Yoshida T, Li J, Owens GK. Smooth muscle cells and myofibroblasts use distinct transcriptional mechanisms for smooth muscle alpha-actin expression. Circ Res 2007; 101: 883-92.
21. Hautmann MB, Madsen CS, Owens GK. A transforming growth factor beta (TGFbeta) control element drives TGFbeta-induced stimulation of smooth muscle alpha-actin gene expression in concert with two CArG elements. J Biol Chem 1997; 272: 10948-56.
22. Leask A, Abraham DJ. TGF-beta signaling and the fibrotic response. FASEB J 2004; 18: 816-27.
23. Shen WL, Gao PJ, Che ZQ, Ji KD, Yin M, Yan C, et al. NAD(P)H oxidase-derived reactive oxygen species regulate angiotensin-II induced adventitial fibroblast phenotypic differentiation. Biochem Biophys Res Commun 2006; 339: 337-43.
24. Shi-Wen X, Chen Y, Denton CP, Eastwood M, Renzoni EA, Bou-Gharios G, et al. Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Mol Biol Cell 2004; 15: 2707-19.
25. Desmouliere A, Redard M, Darby I, Gabbiani G. Apoptosis mediates the decrease in cellularity during the transition between granulation tissue and scar. Am J Pathol 1995; 146: 56-66.
26. Hinz B, Phan SH, Thannickal VJ, Galli A, Bochaton-Piallat ML, Gabbiani G. The myofibroblast. One function, multiple origins. Am J Pathol 2007.
27. Ashley EA, Ferrara R, King JY, Vailaya A, Kuchinsky A, He X, et al. Network analysis of human in-stent restenosis. Circulation 2006; 114: 2644-54.
28. Monraats PS, R P Agema W, Jukema JW. Genetic predictive factors in restenosis. Pathol Biol (Paris) 2004; 52: 186-95.
29. Lal BK. Recurrent carotid stenosis after CEA and CAS: diagnosis and management. Semin Vasc Surg 2007; 20: 259-66.
30. Lal BK, Hobson RW 2nd. Treatment of carotid artery disease: stenting or surgery. Curr Neurol Neurosci Rep 2007; 7: 49-53.
31. Martens TP, Argenziano M, Oz MC. New technology for surgical coronary revascularization. Circulation 2006; 114: 606-14.
32. Gruntzig A, Schneider HJ. The percutaneous dilatation of chronic coronary stenoses-experiments and morphology. Schweiz Med Wochenschr 1977; 107: 1588.
33. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773-80.
34. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al. Sirolimus-eluting stents vs. standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315-23.
35. Stone GW, Ellis SG, Cannon L, Mann JT, Greenberg JD, Spriggs D, et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA 2005; 294: 1215-23.
36. Kuchulakanti PK, Chu WW, Torguson R, Clavijo L, Wolfram R, Mishra S, et al. Sirolimus-eluting stents vs. Paclitaxel-eluting stents in the treatment of coronary artery disease in patients with diabetes mellitus. Am J Cardiol 2006; 98: 187-92.
37. Melikian N, Wijns W. Drug-eluting stents: a critique. Heart 2008; 94: 145-52.
38. Pfisterer M, Brunner-La RHP, Buser PT, Rickenbacher P, Hunziker P, Mueller C, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting vs. bare-metal stents. J Am Coll Cardiol 2006; 48: 2584-91.
39. Camenzind E. Treatment of in-stent restenosis - back to the future? N Engl J Med 2006; 355: 2149-51.
40. Legrand V. Therapy insight: diabetes and drug-eluting stents. Nat Clin Pract Cardiovasc Med 2007; 4: 143-50.
41. Zhang Z, Mahoney EM, Spertus JA, Booth J, Nugara F, Kolm P, et al. The impact of age on outcomes after coronary artery bypass surgery vs. stent-assisted percutaneous coronary intervention: one-year results from the Stent or Surgery (SoS) trial. Am Heart J 2006; 152: 1153-60.
42. Buszman P, Szkrobka I, Gruszka A, Parma R, Tendera Z, Lesko B, et al. Comparison of effectiveness of coronary artery bypass grafting vs. percutaneous coronary intervention in patients with ischemic cardiomyopathy. Am J Cardiol 2007; 99: 36-41.
43. Kastrup A, Groschel K. Carotid endarterectomy vs. carotid stenting: an updated review of randomized trials and subgroup analyses. Acta Chir Belg 2007; 107: 119-28.
44. Schanzer A, Hoel A, Owens CD, Wake N, Nguyen LL, Conte MS, et al. Restenosis after carotid endarterectomy performed with routine intraoperative duplex ultrasonography and arterial patch closure: a contemporary series. Vasc Endovascular Surg 2007; 41: 200-5.
45. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8: 315-7.
46. Friedenstein AJ, Gorskaja JF, Kulagina NN. Fibroblast precursors in normal and irradiated mouse hematopoietic organs. Exp Hematol 1976; 4: 267-74.
47. Noth U, Schupp K, Heymer A, Kall S, Jakob F, Schutze N, et al. Anterior cruciate ligament constructs fabricated from human mesenchymal stem cells in a collagen type I hydrogel. Cytotherapy 2005; 7: 447-55.
48. Tuan RS, Boland G, Tuli R. Adult mesenchymal stem cells and cell-based tissue engineering. Arthritis Res Ther 2003; 5: 32-45.
49. Sarugaser R, Lickorish D, Baksh D, Hosseini MM, Davies JE. Human umbilical cord perivascular (HUCPV) cells: a source of mesenchymal progenitors. Stem Cells 2005; 23: 220-9.
50. Yoshimura H, Muneta T, Nimura A, Yokoyama A, Koga H, Sekiya I. Comparison of rat mesenchymal stem cells derived from bone marrow, synovium, periosteum, adipose tissue, and muscle. Cell Tissue Res 2007; 327: 449-62.
51. Bonab MM, Alimoghaddam K, Talebian F, Ghaffari SH, Ghavamzadeh A, Nikbin B. Aging of mesenchymal stem cell in vitro. BMC Cell Biol 2006; 7: 14.
52. Honczarenko M, Le Y, Swierkowski M, Ghiran I, Glodek AM, Silberstein LE. Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors. Stem Cells 2006; 24: 1030-41.
53. Rubio D, Garcia S, Paz MF, De la Cueva T, Lopez-Fernandez LA, Lloyd AC, et al. Molecular characterization of spontaneous mesenchymal stem cell transformation. PLoS ONE 2008; 3: e1398.
54. Rubio D, Garcia-Castro J, Martin MC, de la Fuente R, Cigudosa JC, Lloyd AC, et al. Spontaneous human adult stem cell transformation. Cancer Res 2005; 65: 3035-9.
55. Prockop DJ, Olson SD. Clinical trials with adult stem/progenitor cells for tissue repair: let's not overlook some essential precautions. Blood 2007; 109: 3147-51.
56. Ball SG, Shuttleworth CA, Kielty CM. Platelet-derived growth factor receptor-alpha is a key determinant of smooth muscle alpha-actin filaments in bone marrow-derived mesenchymal stem cells. Int J Biochem Cell Biol 2007; 39: 379-91.
57. Herzog EL, Chai L, Krause DS. Plasticity of marrow-derived stem cells. Blood 2003; 102: 3483-93.
58. Gang EJ, Bosnakovski D, Figueiredo CA, Visser JW, Perlingeiro RC. SSEA-4 identifies mesenchymal stem cells from bone marrow. Blood 2007; 109: 1743-51.
59. Zannettino AC, Paton S, Kortesidis A, Khor F, Itescu S, Gronthos S. Human mulipotential mesenchymal/stromal stem cells are derived from a discrete subpopulation of STRO-1bright/CD34/CD45(-)/glycophorin-A-bone marrow cells. Haematologica 2007; 92: 1707-8.
60. Semedo P, Wang PM, Andreucci TH, Cenedeze MA, Teixeira VP, Reis MA, et al. Mesenchymal stem cells ameliorate tissue damages triggered by renal ischemia and reperfusion injury. Transplant Proc 2007; 39: 421-3.
61. Schmidt A, Ladage D, Steingen C, Brixius K, Schinkothe T, Klinz FJ, et al. Mesenchymal stem cells transmigrate over the endothelial barrier. Eur J Cell Biol 2006; 85: 1179-88.
62. Schmidt A, Ladage D, Schinkothe T, Klausmann U, Ulrichs C, Klinz FJ, et al. Basic fibroblast growth factor controls migration in human mesenchymal stem cells. Stem Cells 2006; 24: 1750-8.
63. Ji JF, He BP, Dheen ST, Tay SS. Interactions of chemokines and chemokine receptors mediate the migration of mesenchymal stem cells to the impaired site in the brain after hypoglossal nerve injury. Stem Cells 2004; 22: 415-27.
64. Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V, Cazzanti F, et al. Human mesenchymal stem cells modulate B-cell functions. Blood 2006; 107: 367-72.
65. Rasmusson I, Ringden O, Sundberg B, Le Blanc K. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 2003; 76: 1208-13.
66. Sato K, Ozaki K, Oh I, Meguro A, Hatanaka K, Nagai T, et al. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 2007; 109: 228-34.
67. Chen XC, Shan HW, Qu HL, Ge JB, Ge ZP. Bone marrow mesenchymal stem cell transplantation aggravates postangioplasty aortic restenosis in rats. Zhonghua Xin Xue Guan Bing Za Zhi 2007; 35: 802-6.
68. Nasef A, Chapel A, Mazurier C, Bouchet S, Lopez M, Mathieu N, et al. Identification of IL-10 and TGF-beta transcripts involved in the inhibition of T-lymphocyte proliferation during cell contact with human mesenchymal stem cells. Gene Expr 2007; 13: 217-26.
69. Patel SA, Sherman L, Munoz J, Rameshwar P. Immunological properties of mesenchymal stem cells and clinical implications. Arch Immunol Ther Exp (Warsz) 2008; 56: 1-8.
70. Le Blanc K, Tammik C, Rosendahl K, Zetterberg E, Ringden O. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 2003; 31: 890-6.
71. Potian JA, Aviv H, Ponzio NM, Harrison JS, Rameshwar P. Veto-like activity of mesenchymal stem cells: functional discrimination between cellular responses to alloantigens and recall antigens. J Immunol 2003; 171: 3426-34.
72. Poncelet AJ, Vercruysse J, Saliez A, Gianello P. Although pig allogeneic mesenchymal stem cells are not immunogenic in vitro, intracardiac injection elicits an immune response in vivo. Transplantation 2007; 83: 783-90.
73. Bang OY, Lee JS, Lee PH, Lee G. Autologous mesenchymal stem cell transplantation in stroke patients. Ann Neurol 2005; 57: 874-82.
74. Schinkothe T, Bloch W, Schmidt A. In vitro secreting profile of human mesenchymal stem cells. Stem Cells Dev 2008; 17: 199-206.
75. Kinnaird T, Stabile E, Burnett MS, Lee CW, Barr S, Fuchs S, et al. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ Res 2004; 94: 678-85.
76. Abedin M, Tintut Y, Demer LL. Mesenchymal stem cells and the artery wall. Circ Res 2004; 95: 671-6.
77. Hoshino A, Chiba H, Nagai K, Ishii G, Ochiai A. Human vascular adventitial fibroblasts contain mesenchymal stem/progenitor cells. Biochem Biophys Res Commun 2008; 368: 305-10.
78. Tintut Y, Alfonso Z, Saini T, Radcliff K, Watson K, Bostrom K, et al. Multilineage potential of cells from the artery wall. Circulation 2003; 108: 2505-10.
79. Fox JM, Chamberlain G, Ashton BA, Middleton J. Recent advances into the understanding of mesenchymal stem cell trafficking. Br J Haematol 2007; 137: 491-502.
80. Barbash IM, Chouraqui P, Baron J, Feinberg MS, Etzion S, Tessone A, et al. Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution. Circulation 2003; 108: 863-8.
81. Hamilton TA, Novotny M, Datta S, Mandal P, Hartupee J, Tebo J, et al. Chemokine and chemoattractant receptor expression: post-transcriptional regulation. J Leukoc Biol 2007; 82: 213-9.
82. Chamberlain G, Wright K, Rot A, Ashton B, Middleton J. Murine mesenchymal stem cells exhibit a restricted repertoire of functional chemokine receptors: comparison with human. PLoS ONE 2008; 3: e2934.
83. Cheng Z, Ou L, Zhou X, Li F, Jia X, Zhang Y, et al. Targeted migration of mesenchymal stem cells modified with CXCR4 gene to infarcted myocardium improves cardiac performance. Mol Ther 2008; 16: 571-9.
84. Wang Y, Deng Y, Zhou GQ. SDF-1alpha/CXCR4-mediated migration of systemically transplanted bone marrow stromal cells towards ischemic brain lesion in a rat model. Brain Res 2008; 1195: 104-12.
85. Von Luttichau I, Notohamiprodjo M, Wechselberger A, Peters C, Henger A, Seliger C, et al. Human adult CD34- progenitor cells functionally express the chemokine receptors CCR1, CCR4, CCR7, CXCR5, and CCR10 but not CXCR4. Stem Cells Dev 2005; 14: 329-36.
86. Caplan AI. Adult mesenchymal stem cells for tissue engineering vs. regenerative medicine. J Cell Physiol 2007; 213: 341-7.
87. Giordano A, Galderisi U, Marino IR. From the laboratory bench to the patient's bedside: an update on clinical trials with mesenchymal stem cells. J Cell Physiol 2007; 211: 27-35.
88. Horwitz EM, Prockop DJ, Gordon PL, Koo WW, Fitzpatrick LA, Neel MD, et al. Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta. Blood 2001; 97: 1227-31.
89. Koc ON, Day J, Nieder M, Gerson SL, Lazarus HM, Krivit W. Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH). Bone Marrow Transplant 2002; 30: 215-22.
90. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-vs-host disease: a phase II study. Lancet 2008; 371: 1579-86.
91. Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 1997; 276: 71-4.
92. Ray R, Novotny NM, Crisostomo PR, Lahm T, Abarbanell A, Meldrum DR. Sex steroids and stem cell function. Mol Med 2008; 14: 493-501.
93. Singh R, Artaza JN, Taylor WE, Gonzalez-Cadavid NF, Bhasin S. Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1/ 2 pluripotent cells through an androgen receptor-mediated pathway. Endocrinology 2003; 144: 5081-8.
94. Wang Q, Yu JH, Zhai HH, Zhao QT, Chen JW, Shu L, et al. Temporal expression of estrogen receptor alpha in rat bone marrow mesenchymal stem cells. Biochem Biophys Res Commun 2006; 347: 117-23.
95. Hong L, Colpan A, Peptan IA. Modulations of 17-beta estradiol on osteogenic and adipogenic differentiations of human mesenchymal stem cells. Tissue Eng 2006; 12: 2747-53.
96. Zhou S, Zilberman Y, Wassermann K, Bain SD, Sadovsky Y, Gazit D. Estrogen modulates estrogen receptor alpha and beta expression, osteogenic activity, and apoptosis in mesenchymal stem cells (MSCs) of osteoporotic mice. J Cell Biochem Suppl 2001; (Suppl 36): 144-55.
97. Crisostomo PR, Wang M, Herring CM, Markel TA, Meldrum KK, Lillemoe KD, et al. Gender differences in injury induced mesenchymal stem cell apoptosis and VEGF, TNF, IL-6 expression: role of the 55 kDa TNF receptor (TNFR1). J Mol Cell Cardiol 2007; 42: 142-9.
98. Erwin GS, Crisostomo PR, Wang Y, Wang M, Markel TA, Guzman M, et al. Estradiol-Treated Mesenchymal Stem Cells Improve Myocardial Recovery After Ischemia. J Surg Res 2009; 152: 319-24.
99. Chen L, Tredget EE, Wu PY, Wu Y. Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PLoS ONE 2008; 3: e1886.
100. Wu X, Huang L, Zhou Q, Song Y, Li A, Jin J, et al. Mesenchymal stem cells participating in ex vivo endothelium repair and its effect on vascular smooth muscle cells growth. Int J Cardiol 2005; 105: 274-82.
101. Wu X, Huang L, Zhou Q, Song Y, Li A, Wang H, et al. Effect of paclitaxel and mesenchymal stem cells seeding on ex vivo vascular endothelial repair and smooth muscle cells growth. J Cardiovasc Pharmacol 2005; 46: 779-86.
102. Hashi CK, Zhu Y, Yang GY, Young WL, Hsiao BS, Wang K, et al. Antithrombogenic property of bone marrow mesenchymal stem cells in nanofibrous vascular grafts. Proc Natl Acad Sci USA 2007; 104: 11915-20.
103. Mirza A, Hyvelin JM, Rochefort GY, Lermusiaux P, Antier D, Awede B, et al. Undifferentiated mesenchymal stem cells seeded on a vascular prosthesis contribute to the restoration of a physiologic vascular wall. J Vasc Surg 2008; 47: 1313-21.
104. Forte A, Finicelli M, Mattia M, Berrino L, Rossi F, De Feo M, et al. Mesenchymal stem cells effectively reduce surgically induced stenosis in rat carotids. J Cell Physiol 2008; 217: 789-99.
105. Wang T, Xu Z, Jiang W, Ma A. Cell-to-cell contact induces mesenchymal stem cell to differentiate into cardiomyocyte and smooth muscle cell. Int J Cardiol 2006; 109: 74-81.
106. Nakanishi C, Yamagishi M, Yamahara K, Hagino I, Mori H, Sawa Y, et al. Activation of cardiac progenitor cells through paracrine effects of mesenchymal stem cells. Biochem Biophys Res Commun 2008; 374: 11-6.
107. Kinnaird T, Stabile E, Burnett MS, Shou M, Lee CW, Barr S, et al. Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms. Circulation 2004; 109: 1543-9.
108. Schrepfer S, Deuse T, Reichenspurner H, Fischbein MP, Robbins RC, Pelletier MP. Stem cell transplantation: the lung barrier. Transplant Proc 2007; 39: 573-6.
109. Gao J, Dennis JE, Muzic RF, Lundberg M, Caplan AI. The dynamic distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs 2001; 169: 12-20.
110. Psaltis PJ, Zannettino A, Worthley SG, Gronthos S. Mesenchymal Stromal Cells - Potential for Cardiovascular Repair. Stem Cells 2008; 26: 2201-10.
111. Lee PH, Kim JW, Bang OY, Ahn YH, Joo IS, Huh K. Autologous mesenchymal stem cell therapy delays the progression of neurological deficits in patients with multiple system atrophy. Clin Pharmacol Ther 2008; 83: 723-30.
112. Ma J, Ge J, Zhang S, Sun A, Shen J, Chen L, et al. Time course of myocardial stromal cell-derived factor 1 expression and beneficial effects of intravenously administered bone marrow stem cells in rats with experimental myocardial infarction. Basic Res Cardiol 2005; 100: 217-23.
113. Goumans MJ, Lebrin F, Valdimarsdottir G. Controlling the angiogenic switch: a balance between two distinct TGF-b receptor signaling pathways. Trends Cardiovasc Med 2003; 13: 301-7.
114. Pepper MS, Vassalli JD, Orci L, Montesano R. Biphasic effect of transforming growth factor-beta 1 on in vitro angiogenesis. Exp Cell Res 1993; 204: 356-63.
115. Frid MG, Kale VA, Stenmark KR. Mature vascular endothelium can give rise to smooth muscle cells via endothelial-mesenchymal transdifferentiation: in vitro analysis. Circ Res 2002; 90: 1189-96.
116. Hautmann MB, Adam PJ, Owens GK. Similarities and differences in smooth muscle alpha-actin induction by TGF-beta in smooth muscle vs. non-smooth muscle cells. Arterioscler Thromb Vasc Biol 1999; 19: 2049-58.
117. Majesky MW, Lindner V, Twardzik DR, Schwartz SM, Reidy MA. Production of transforming growth factor beta 1 during repair of arterial injury. J Clin Invest 1991; 88: 904-10.
118. Schulick AH, Taylor AJ, Zuo W, Qiu CB, Dong G, Woodward RN, et al. Overexpression of transforming growth factor beta1 in arterial endothelium causes hyperplasia, apoptosis, and cartilaginous metaplasia. Proc Natl Acad Sci USA 1998; 95: 6983-8.
119. Smith JD, Bryant SR, Couper LL, Vary CP, Gotwals PJ, Koteliansky VE, et al. Soluble transforming growth factor-beta type II receptor inhibits negative remodeling, fibroblast transdifferentiation, and intimal lesion formation but not endothelial growth. Circ Res 1999; 84: 1212-22.
120. McCaffrey TA, Du B, Consigli S, Szabo P, Bray PJ, Hartner L, et al. Genomic instability in the type II TGF-beta1 receptor gene in atherosclerotic and restenotic vascular cells. J Clin Invest 1997; 100: 2182-8.
121. Grainger DJ, Kemp PR, Metcalfe JC, Liu AC, Lawn RM, Williams NR, et al. The serum concentration of active transforming growth factor-beta is severely depressed in advanced atherosclerosis. Nat Med 1995; 1: 74-9.
122. Mallat Z, Gojova A, Marchiol-Fournigault C, Esposito B, Kamate C, Merval R, et al. Inhibition of transforming growth factor-beta signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice. Circ Res 2001; 89: 930-4.
123. Rey FE, Li XC, Carretero OA, Garvin JL, Pagano PJ. Perivascular superoxide anion contributes to impairment of endothelium-dependent relaxation: role of gp91(phox). Circulation 2002; 106: 2497-502.
124. Haurani MJ, Pagano PJ. Adventitial fibroblast reactive oxygen species as autacrine and paracrine mediators of remodeling: bell-wether for vascular disease? Cardiovasc Res 2007; 75: 679-89.
125. Kim WS, Park BS, Kim HK, Park JS, Kim KJ, Choi JS, et al. Evidence supporting antioxidant action of adipose-derived stem cells: protection of human dermal fibroblasts from oxidative stress. J Dermatol Sci 2008; 49: 133-42.
126. Kuo TK, Hung SP, Chuang CH, Chen CT, Shih YR, Fang SC, et al. Stem cell therapy for liver disease: parameters governing the success of using bone marrow mesenchymal stem cells. Gastroenterology 2008; 134: 2111-21, 21 e1-3.
127. Yue WM, Liu W, Bi YW, He XP, Sun WY, Pang XY, et al. Mesenchymal stem cells differentiate into an endothelial phenotype, reduce neointimal formation, and enhance endothelial function in a rat vein grafting model. Stem Cells Dev 2008; 17: 785-93.
128. Kanki-Horimoto S, Horimoto H, Mieno S, Kishida K, Watanabe F, Furuya E, et al. Synthetic vascular prosthesis impregnated with mesenchymal stem cells overexpressing endothelial nitric oxide synthase. Circulation 2006; 114(1 Suppl): I327-30.
129. Kanki-Horimoto S, Horimoto H, Mieno S, Kishida K, Watanabe F, Furuya E, et al. Implantation of mesenchymal stem cells overexpressing endothelial nitric oxide synthase improves right ventricular impairments caused by pulmonary hypertension. Circulation 2006; 114(1 Suppl): I181-5.
130. Vincentelli A, Wautot F, Juthier F, Fouquet O, Corseaux D, Marechaux S, et al. In vivo autologous recellularization of a tissue-engineered heart valve: are bone marrow mesenchymal stem cells the best candidates? J Thorac Cardiovasc Surg 2007; 134: 424-32.
131. Wang CH, Cherng WJ, Yang NI, Kuo LT, Hsu CM, Yeh HI, et al. Late-outgrowth endothelial cells attenuate intimal hyperplasia contributed by mesenchymal stem cells after vascular injury. Arterioscler Thromb Vasc Biol 2008; 28: 54-60.
132. Miura M, Miura Y, Padilla-Nash HM, Molinolo AA, Fu B, Patel V, et al. Accumulated chromosomal instability in murine bone marrow mesenchymal stem cells leads to malignant transformation. Stem Cells 2006; 24: 1095-103.
133. Lepperdinger G, Brunauer R, Jamnig A, Laschober G, Kassem M. Controversial issue: Is it safe to employ mesenchymal stem cells in cell-based therapies? Exp Gerontol 2008; 43: 1018-23.
134. Kong D, Melo LG, Gnecchi M, Zhang L, Mostoslavsky G, Liew CC, et al. Cytokine-induced mobilization of circulating endothelial progenitor cells enhances repair of injured arteries. Circulation 2004; 110: 2039-46.
135. Forte A, Napolitano MA, Cipollaro M, Giordano A, Cascino A, Galderisi U. An effective method for adenoviral-mediated delivery of small interfering RNA into mesenchymal stem cells. J Cell Biochem 2007; 100: 293-302.
136. Wallitt EJ, Jevon M, Hornick PI. Therapeutics of vein graft intimal hyperplasia: 100 years on. Ann Thorac Surg 2007; 84: 317-23.